U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C29H35N4O5.Ca
Molecular Weight 1079.302
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NASTORAZEPIDE CALCIUM

SMILES

[Ca++].CC(C)(C)C(=O)CN1C2=CC=CC=C2N(C[C@@H](NC(=O)NC3=CC(=CC=C3)C([O-])=O)C1=O)C4CCCCC4.CC(C)(C)C(=O)CN5C6=CC=CC=C6N(C[C@@H](NC(=O)NC7=CC(=CC=C7)C([O-])=O)C5=O)C8CCCCC8

InChI

InChIKey=DLRNGUKRKXEPEL-LJWMURKVSA-L
InChI=1S/2C29H36N4O5.Ca/c2*1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37;/h2*7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38);/q;;+2/p-2/t2*22-;/m11./s1

HIDE SMILES / InChI

Molecular Formula C29H35N4O5
Molecular Weight 519.612
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800016682 | http://www.zeria.co.jp/english/comp/co_0501.html |

Nastorazepide (Z-360) is a selective, orally available, gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. It is currently under development as a therapeutic drug for pancreatic cancer, gastroesophageal reflux disease and peptic ulcers. The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue.

Originator

Curator's Comment: http://www.zeria.co.jp/english/comp/co_0501.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.47 nM [Kd]
Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4434 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6756 ng/mL
240 mg single, oral
dose: 240 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18600 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
24030 ng × h/mL
240 mg single, oral
dose: 240 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.17 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.5 h
240 mg single, oral
dose: 240 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NASTORAZEPIDE CALCIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [IC50 10 uM]
yes [IC50 1 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
2011 Oct 24
Patents

Sample Use Guides

60, 120 or 240 mg, twice daily (28-day cycle).
Route of Administration: Oral
In PANC-1 cells, gemcitabineinduced expression of HIF-1alpha gene was suppressed by treatment with 0.1 μM Z-360.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:31:20 GMT 2023
Edited
by admin
on Sat Dec 16 10:31:20 GMT 2023
Record UNII
GZ3I1DMI8Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NASTORAZEPIDE CALCIUM
Common Name English
NASTORAZEPIDE HEMICALCIUM
Common Name English
(R)-3-(3-(5-CYCLOHEXYL-1-(3,3-DIMETHYL-2-OXOBUTYL)-2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO(B)(1,4)DIAZEPIN-3-YL)UREIDO)BENZOIC ACID
Systematic Name English
Z-360
Common Name English
R-(-)-Z-360
Common Name English
BENZOIC ACID, 3-(((((3R)-5-CYCLOHEXYL-1-(3,3-DIMETHYL-2-OXOBUTYL)-2,3,4,5-TETRAHYDRO-2-OXO-1H-1,5-BENZODIAZEPIN-3-YL)AMINO)CARBONYL)AMINO)-, CALCIUM SALT (2:1)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129824
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID40187905
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
PRIMARY
NCI_THESAURUS
C61329
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
PRIMARY NCIT
CAS
343326-69-2
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
PRIMARY
PUBCHEM
10170574
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
PRIMARY
FDA UNII
GZ3I1DMI8Q
Created by admin on Sat Dec 16 10:31:20 GMT 2023 , Edited by admin on Sat Dec 16 10:31:20 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY